A new entity has recently been defined; it concerns the subpopulation of breast cancers which weakly express the HER2 receptors (HER2 immunohistochemistry 1+ or 2+, but ISH negative) and which were considered until a few years ago as HER2-negative breast cancer [66]. Here, ERBB2 is linked to breast cancer.